| Good practices in model‐informed drug discovery and development: practice, application, and documentation EFPIA MID3 Workgroup, SF Marshall, R Burghaus, V Cosson, ... CPT: pharmacometrics & systems pharmacology 5 (3), 93-122, 2016 | 257 | 2016 |
| Predictions of metabolic drug-drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil N Perdaems, H Blasco, C Vinson, M Chenel, S Whalley, F Cazade, ... Clinical pharmacokinetics 49, 239-258, 2010 | 75 | 2010 |
| Integrated pharmacokinetic/pharmacodynamic model of a bispecific CD3xCD123 DART molecule in nonhuman primates: evaluation of activity and impact of immunogenicity O Campagne, A Delmas, S Fouliard, M Chenel, GR Chichili, H Li, ... Clinical Cancer Research 24 (11), 2631-2641, 2018 | 63 | 2018 |
| Quantitative Systems Pharmacology approaches for Immuno‐oncology: adding virtual patients to the development paradigm V Chelliah, G Lazarou, S Bhatnagar, JP Gibbs, M Nijsen, A Ray, B Stoll, ... Clinical Pharmacology & Therapeutics, 2020 | 51 | 2020 |
| Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm J Bertrand, E Comets, CM Laffont, M Chenel, F Mentré Journal of pharmacokinetics and pharmacodynamics 36, 317-339, 2009 | 45 | 2009 |
| Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ... CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015 | 41 | 2015 |
| Current use and developments needed for optimal design in pharmacometrics: a study performed among DDMoRe's European Federation of Pharmaceutical Industries and Associations … F Mentré, M Chenel, E Comets, J Grevel, A Hooker, MO Karlsson, ... CPT: pharmacometrics & systems pharmacology 2 (6), 1-2, 2013 | 41 | 2013 |
| Development of a complex parent-metabolite joint population pharmacokinetic model J Bertrand, CM Laffont, F Mentré, M Chenel, E Comets The AAPS journal 13, 390-404, 2011 | 35 | 2011 |
| Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results M Chenel, F Bouzom, F Cazade, K Ogungbenro, L Aarons, F Mentre Journal of Pharmacokinetics and Pharmacodynamics 6 (35), 661-81, 2008 | 35 | 2008 |
| Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I S Fouliard, R Robert, A Jacquet-Bescond, QC du Rieu, ... European journal of cancer 49 (13), 2791-2797, 2013 | 33 | 2013 |
| Optimal Sampling Times for a Drug and its Metabolite using SIMCYP® Simulations as Prior Information C Dumont, F Mentré, C Gaynor, K Brendel, C Gesson, M Chenel Clinical pharmacokinetics 52, 43-57, 2013 | 33 | 2013 |
| Development of a physiologically-based pharmacokinetic model of the rat central nervous system RKS Badhan, M Chenel, JI Penny Pharmaceutics 6 (1), 97-136, 2014 | 30 | 2014 |
| Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates F Simon, E Gautier-Veyret, A Truffot, M Chenel, L Payen, ... Pharmaceutical Research 38, 415-428, 2021 | 27 | 2021 |
| Impact of interleukin-6 on drug-metabolizing enzymes and transporters in intestinal cells F Simon, J Garcia, L Guyot, J Guitton, G Vilchez, C Bardel, M Chenel, ... The AAPS journal 22, 1-10, 2020 | 26 | 2020 |
| Some alternatives to asymptotic tests for the analysis of pharmacogenetic data using nonlinear mixed effects models J Bertrand, E Comets, M Chenel, F Mentré Biometrics 68 (1), 146-155, 2012 | 26 | 2012 |
| Simultaneous central nervous system distribution and pharmacokinetic–pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant … M Chenel, S Marchand, A Dupuis, I Lamarche, J Paquereau, C Pariat, ... British journal of pharmacology 142 (2), 323-330, 2004 | 26 | 2004 |
| Getting innovative therapies faster to patients at the right dose: impact of quantitative pharmacology towards first registration and expanding therapeutic use S Nayak, O Sander, N Al‐Huniti, D de Alwis, A Chain, M Chenel, ... Clinical Pharmacology & Therapeutics 103 (3), 378-383, 2018 | 23 | 2018 |
| Pharmacokinetic modeling of free amoxicillin concentrations in rat muscle extracellular fluids determined by microdialysis S Marchand, M Chenel, I Lamarche, W Couet Antimicrobial agents and chemotherapy 49 (9), 3702-3706, 2005 | 22 | 2005 |
| Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats S Marchand, M Chenel, I Lamarche, C Pariat, W Couet Journal of pharmaceutical sciences 92 (12), 2458-2465, 2003 | 22 | 2003 |
| Impact of hepatic CYP3A4 ontogeny functions on drug–drug interaction risk in pediatric physiologically‐based pharmacokinetic/pharmacodynamic modeling: Critical literature … J Lang, L Vincent, M Chenel, K Ogungbenro, A Galetin Clinical Pharmacology & Therapeutics 109 (6), 1618-1630, 2021 | 20 | 2021 |
